A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment

Peer Review reports

Original Submission
1 Dec 2017	Submitted	Original manuscript
20 Dec 2017	Author responded	Author comments - Janet Rea Hardy
Resubmission - Version 2
20 Dec 2017	Submitted	Manuscript version 2
30 Jan 2018	Reviewed	Reviewer Report - David Warr
1 Feb 2018	Reviewed	Reviewer Report - Dorothy Keefe
2 Feb 2018	Reviewed	Reviewer Report - Paz Fernández-Ortega
2 Mar 2018	Author responded	Author comments - Janet Rea Hardy
Resubmission - Version 3
2 Mar 2018	Submitted	Manuscript version 3
13 Mar 2018	Reviewed	Reviewer Report - David Warr
20 Mar 2018	Reviewed	Reviewer Report - Paz Fernández-Ortega
13 Apr 2018	Author responded	Author comments - Janet Rea Hardy
Resubmission - Version 4
13 Apr 2018	Submitted	Manuscript version 4
17 Apr 2018	Author responded	Author comments - Janet Rea Hardy
Resubmission - Version 5
17 Apr 2018	Submitted	Manuscript version 5
Publishing
18 Apr 2018	Editorially accepted
2 May 2018	Article published	10.1186/s12885-018-4404-8

Back to article page